ADC Therapeutics SA Earnings Recaps
Q3 2025
Nov 10, 2025
ADC Therapeutics reported steady net product revenues of $15.8 million in Q3 2025, reflecting consistent demand for its lead product, ZENLATA, while positioning for future growth through ongoing clinical trials and recent financing.
Key takeaways
- Net product revenues were stable, matching quarterly run rates from the previous two years.
- Secured a $60 million private placement, extending the cash runway into 2028.
- Multiple ongoing clinical trials for ZENLATA are expected to bolster its market position, with potential expansions into earlier treatment lines and additional lymphoma types.
- Anticipation for upcoming data releases from key trials, including LOTUS V and LOTUS seven, which could enhance revenue projections significantly.
- Long-term peak annual revenue for ZENLATA is estimated between $600 million and $1 billion, contingent on successful trial outcomes and market expansion.
Q2 2025
Aug 12, 2025
ADC Therapeutics reported solid Q2 2025 performance, with net product revenues reaching $18.1 million, and promising clinical data for its ZYNLONTA treatments positioning the company for significant growth.
Key takeaways
- Net product revenues increased slightly year-over-year to $18.1 million in Q2 and $35.5 million in the first half of 2025.
- ZYNLONTA plus glofitamab demonstrated a remarkable overall response rate of 93.3% in the LOTIS-7 trial, with plans to expand enrollment to 100 patients.
- The company is streamlining its operations by focusing solely on ZYNLONTA and a PSMA-targeting ADC, leading to a 30% workforce reduction.
- Continued development in late-stage trials is expected; LOTIS-5 is on track for key data by year-end 2025, potentially enhancing ZYNLONTA's market footprint.
- The completion of a $100 million private placement extends the company’s cash runway into 2028, supporting its strategic initiatives and growth plans.